Advertisement

Topics

Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma

15:00 EDT 16 May 2019 | Drugs.com

THURSDAY, May 16, 2019 -- Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced. The agency based the approval on data...

Original Article: Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma

NEXT ARTICLE

More From BioPortfolio on "Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...